Pharmacokinetics of Neostigmine and Pyridostigmine in Man and Its Correlation to Clinical Effects in Myasthenia Gravis
Cholinesterase inhibitors, such as neostigmine and pyridostigine, have been in clinical use for more than 40 years as the basic medical treatment in myasthenia gravis. The first investigation of the basic pharmacokinetics was performed by Kornfeld et al. (7) with l4C-labelled pyridostigmine. Later, two different gas chromatographic (GC) procedures for the assay of neostigmine and pyridostigmine were described by Chan et al. (3) and Cohen et al. (6). None of these methods, however, seems to be sufficiently sensitive or selective to permit accurate determination of neostigmine and pyridostigmine in the plasma of myasthenic patients receiving oral treatment.
KeywordsPlasma Concentration Intravenous Administration Cholinesterase Inhibitor Steady State Plasma Concentration Myasthenic Patient
Unable to display preview. Download preview PDF.